Latest news with #Dr.Reddy'sLaboratories
Business Upturn
2 days ago
- Business
- Business Upturn
Dr. Reddy's Laboratorie gets EIR from USFDA for Telangana facility with VAI status
By Aman Shukla Published on August 8, 2025, 16:24 IST Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API manufacturing facility (CTO 5) in Miryalaguda, Telangana. The EIR was issued on August 7, 2025, following a GMP inspection that was earlier conducted and disclosed by the company on May 24, 2025. The USFDA has classified the outcome of the inspection as 'Voluntary Action Indicated (VAI)' , meaning the agency has closed the inspection with some observations, but no further regulatory action is anticipated at this time. The inspection is officially considered closed under 21 CFR 20.64(d)(3). A VAI classification typically indicates that the facility remains compliant for continued supply to the US market. This update should bring some regulatory clarity and comfort to stakeholders and investors. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
01-08-2025
- Business
- Business Upturn
Nifty 50 top losers today, August 1: Sun Pharma, Dr. Reddy's Laboratories, Adani Enterprises, Cipla and more
Indian equity markets ended Friday's session (August 1) on a weak note, with both benchmark indices registering sharp declines. The BSE Sensex fell 585.67 points to settle at 80,599.91, while the NSE Nifty 50 dropped 203 points to close at 24,565.35. Among the top laggards of the day were Sun Pharma, Dr. Reddy's Laboratories, Adani Enterprises, and Cipla, all of which saw notable declines. Let's take a closer look at the top losers of the Nifty 50, according to Trendlyne. Nifty 50 top losers on August 1 Sun Pharmaceutical closed at ₹1,629.3, down 4.5% Dr. Reddy's Laboratories ended at ₹1,221.4, falling 3.9% Adani Enterprises settled at ₹2,341.5, losing 3.7% Cipla closed at ₹1,505.0, down 3.2% Tata Steel ended at ₹153.0, slipping 3.1% Infosys closed at ₹1,468.3, down 2.7% Maruti Suzuki India ended at ₹12,275.0, falling 2.6% Tata Motors settled at ₹649.7, down 2.4% Shriram Finance closed at ₹615.7, falling 2.4% Wipro ended at ₹242.4, slipping 2.4% Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Adani enterprisesCiplaDr Reddy's LaboratoriesStock MarketSun Pharma Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
24-07-2025
- Business
- Business Upturn
Nifty top gainers today, July 24: Eternal, Dr. Reddy's Laboratories, Tata Motors, Tata Consumer Products and more
By Aman Shukla Published on July 24, 2025, 15:38 IST Indian benchmark indices ended lower on July 24, with the Sensex slipping 542.47 points to settle at 82,184.17, and the Nifty closing 157.80 points down at 25,062.10. However, a few heavyweight stocks from the Nifty 50 pack managed to defy the broader market trend and posted notable gains. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day. Nifty 50 Top Gainers on July 24 Eternal closed at ₹312.5, up 3.4% Dr. Reddy's Laboratories ended at ₹1,268.9, up 1.7% Tata Motors closed at ₹701.3, up 1.6% Tata Consumer Products ended at ₹1,073.0, up 1.0% Cipla closed at ₹1,486.3, up 0.9% Grasim Industries settled at ₹2,729.2, up 0.7% Jio Financial Services ended at ₹316.5, up 0.7% Eicher Motors closed at ₹5,472.5, up 0.6% Sun Pharmaceutical ended at ₹1,692.0, up 0.6% Tata Steel closed at ₹163.6, up 0.5% Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Dr Reddy's LaboratoriesEternalTata Consumer ProductsTata Motors Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Hans India
24-07-2025
- Business
- Hans India
Indian stock market opens flat, IT stocks under pressure
Mumbai: The Indian stock market opened flat on Thursday as IT companies experienced selling pressure amid mixed global cues. At 9.28 am, Sensex slipped 110 points or 0.13 per cent to 82,615 and Nifty slipped 13 points or 0.05 per cent to 25,206. Sectorally, Nifty IT underperformed with a loss of 1.17 per cent. All other sectors show marginal dips to moderate gains. Bank stocks showed moderate losses up to 0.20 per cent. Midcap and smallcap stocks saw selling pressure. Nifty midcap 100 index was down 0.39 per cent at 59,148 and Nifty smallcap 100 index was down 0.07 per cent at 18,879. In the Nifty pack, Dr. Reddy's Laboratories led the gainers (3.07 per cent), followed by Tata Motors (1.51 per cent). Tata Consumer Products, Eicher Motors, JSW Steel and Tata Steel were other major gainers. Trent, Kotak Mahindra Bank, and Bajaj Finance were among losers in early trade. "Market sentiment remains cautiously optimistic amid heightened volatility and mixed global cues. Nifty 50's rebound highlights buyer strength at lower levels. A sustained move above 25,250 could potentially open the path toward the 25,330 mark. On the downside, immediate support is placed at 25,125, followed by 25,000," said Hardik Matalia from Choice Equity Broking Private Limited. The Bank Nifty outperformed the broader index, rising 454 points and forming a bullish candlestick, indicating renewed buying interest, he added. Both Asian and US indices posted strong overnight gains, lending a positive backdrop for Indian markets as they open. In the US, the Dow Jones Industrial Average advanced 1.14 per cent. Nasdaq rose 0.61 per cent, and the S&P 500 added 0.78 per cent. According to analysts, the US striking trade deals with many countries is slowly removing concerns surrounding tariff wars. Good corporate earnings in the US are providing the fundamental support to the market. In Asian markets, the Nikkei 225 continued a huge upswing for the second consecutive day (1.97 percent), and Indonesia's Jakarta Composite climbed 1.70 per cent. Hong Kong, Shanghai and Seoul were in the green zone. On July 23, foreign institutional investors (FIIs) were net sellers for the fifth consecutive session, offloading stocks worth Rs 4,209 crore. In contrast, domestic institutional investors (DIIs) remained strong buyers for the 12th straight day. They net purchased shares worth Rs 4,358 crore.
Business Upturn
24-07-2025
- Business
- Business Upturn
Dr. Reddy's shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More
By Aditya Bhagchandani Published on July 24, 2025, 09:37 IST Shares of Dr. Reddy's Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands a market capitalization of Rs 1.07 lakh crore. For the quarter ended June 30, 2025, the pharmaceutical major posted a consolidated net profit of Rs 1,418 crore, up 2% year-on-year. Revenue from operations stood at Rs 8,545 crore, reflecting an 11% YoY increase, primarily driven by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and steady performance in branded markets. However, profit declined 11% quarter-on-quarter, while revenue remained flat sequentially. EBITDA for the quarter was Rs 2,280 crore, marking a 5% YoY increase, though EBITDA margin slipped 530 basis points to 56.9%, largely due to pricing pressure in the US generics segment and lower operating leverage. The Global Generics segment recorded Rs 7,560 crore in revenue, up 10% YoY, but remained unchanged QoQ. Revenue from North America declined 11% YoY to Rs 3,410 crore amid price erosion in key generics like Lenalidomide. Meanwhile, India revenue grew 11% YoY to Rs 1,470 crore, aided by new launches and pricing strategies. European business saw a sharp 142% YoY jump to Rs 1,270 crore, driven by the NRT acquisition and product launches. Brokerages offered a cautious outlook on Dr. Reddy's Laboratories following its Q1 FY26 results, primarily due to concerns over the US generics business. CLSA and Jefferies both retained their 'Underperform' ratings, with target prices of Rs 1,120 and Rs 1,100 respectively. CLSA noted that while overall earnings were in line with expectations, the US base business is expected to remain flat or grow in low single digits year-on-year, with Revlimid sales likely tapering off from Q3FY26. Jefferies flagged a miss in Q1 estimates due to a sharper-than-expected decline in US sales, driven by lower revenues from gRevlimid and sustained pressure in the base portfolio. Elevated SG&A and R&D spending also weighed on margins. However, it highlighted upcoming launches such as gOzempic in Canada and the US filing for Abatacept as key triggers to watch. Meanwhile, Morgan Stanley maintained an 'Equal-weight' rating with a target price of Rs 1,298, acknowledging steady growth in most markets but citing generic price erosion and reduced operating leverage as drag factors on margin. Dr. Reddy's Q1 YoY Comparison Table (in Rs crore): Metric Q1 FY26 Q1 FY25 YoY % Change Revenue from Operations 8,545 7,700 11% Net Profit 1,418 1,390 2% EBITDA 2,280 2,170 5% EBITDA Margin (%) 56.9% 62.2% -530 bps Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
